| P2093 | author name string | Wakoh Takahashi | |
| | Fumihito Yoshii | |
| | Masafuchi Ryo | |
| | Tomohide Ohnuki | |
| | Yusuke Moriya | |
| P2860 | cites work | Fingolimod for relapsing-remitting multiple sclerosis | Q24185882 |
| | Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence | Q26752466 |
| | Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations | Q26765300 |
| | Progressive multifocal leukoencephalopathy: current treatment options and future perspectives | Q26776236 |
| | Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment | Q26777684 |
| | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities | Q26781389 |
| | Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab | Q26851341 |
| | A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 |
| | Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 |
| | Classifying PML risk with disease modifying therapies | Q30235337 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | Fingolimod therapy for multiple sclerosis | Q30633055 |
| | Tumefactive MS lesions under fingolimod: a case report and literature review | Q30671543 |
| | Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial | Q30789784 |
| | Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases | Q30815289 |
| | Fingolimod for multiple sclerosis | Q34140875 |
| | Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment | Q34158293 |
| | Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 |
| | Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? | Q34365360 |
| | Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions | Q34459784 |
| | PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation | Q34650456 |
| | Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 |
| | Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report | Q34963426 |
| | Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). | Q35052199 |
| | Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial | Q35136988 |
| | Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 |
| | Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy | Q35675602 |
| | Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption | Q35728024 |
| | Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS | Q35938575 |
| | Neuromyelitis optica spectrum disorder (NMOSD): A new concept. | Q36011746 |
| | Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 |
| | Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study | Q36262843 |
| | Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. | Q36314901 |
| | Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study | Q36859528 |
| | Fingolimod-associated PML in a patient with prior immunosuppression | Q36887160 |
| | Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features | Q37403424 |
| | Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod | Q37475542 |
| | Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension | Q37548575 |
| | The pathological spectrum of CNS inflammatory demyelinating diseases | Q37603085 |
| | Fingolimod after natalizumab and the risk of short-term relapse | Q37725909 |
| | Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis | Q38468632 |
| | Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). | Q38577593 |
| | No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. | Q38754429 |
| | Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis | Q38793391 |
| | Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment | Q38822967 |
| | Neuromyelitis Optica (Devic's Syndrome): an Appraisal | Q38893206 |
| | Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy | Q39163313 |
| | Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. | Q39211049 |
| | JCV serology in time: 3 years of follow-up | Q39263983 |
| | Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases | Q40922077 |
| | Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis | Q41057804 |
| | Rebound exacerbation multiple sclerosis following cessation of oral treatment | Q41067948 |
| | Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings | Q41069054 |
| | Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation | Q41295068 |
| | MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. | Q41361912 |
| | A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis | Q41411445 |
| | Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy | Q41595215 |
| | Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy | Q41598188 |
| | Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc | Q41860847 |
| | Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. | Q42144320 |
| | Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. | Q42176597 |
| | Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. | Q44017725 |
| | Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy. | Q44323297 |
| | Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange | Q44473997 |
| | Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. | Q44735512 |
| | A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment | Q45758717 |
| | Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod | Q48319736 |
| | Tumefactive multiple sclerosis lesions under fingolimod treatment | Q48350609 |
| | Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal | Q48403712 |
| | Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences | Q48418031 |
| | Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? | Q48622816 |
| | Tumefactive multiple sclerosis and fingolimod | Q48679048 |
| | Severe tumefactive rebound of multiple sclerosis following fingolimod cessation | Q48694924 |
| | Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder | Q48708490 |
| | Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder | Q48795303 |
| | Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. | Q51158406 |
| | Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report | Q56673459 |
| | Severe relapses under fingolimod treatment prescribed after natalizumab | Q61231049 |
| | A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis | Q83485793 |
| | Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis | Q84038259 |
| | Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 |
| | [A case of multiple sclerosis who relapsed early after fingolimod therapy introduced] | Q85444170 |
| | Rebound of disease activity during pregnancy after withdrawal of fingolimod | Q87049318 |
| | Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy | Q87263098 |
| | Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia | Q87732233 |
| | Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod | Q89251032 |
| | Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod | Q89359174 |
| | Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis | Q89915689 |
| | Re: Tumefactive multiple sclerosis lesions under fingolimod treatment | Q95803338 |
| P433 | issue | 3 | |
| P304 | page(s) | 233-243 | |
| P577 | publication date | 2017-06-18 | |
| P1433 | published in | Clinical & experimental neuroimmunology | Q27724454 |
| P1476 | title | Neurological safety of fingolimod: An updated review | |
| P478 | volume | 8 | |